Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
Hims & Hers (HIMS) is expanding its telehealth product portfolio with compounded peptide treatments including sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine. Notably, none of these compounds carry FDA approval, positioning this as an off-label or direct-to-consumer wellness play rather than a clinically validated therapeutic intervention.
The strategic signal is mixed: the company is capitalizing on growing consumer interest in longevity and performance-enhancement compounds, a segment demonstrating robust demand outside traditional pharmaceutical channels. However, the explicit admission that efficacy data remains incomplete introduces regulatory and reputational risk—the FDA has scrutinized telehealth operators offering unapproved peptides, and any enforcement action or market backlash could pressure both revenue and brand equity.
This move reflects HIMS's business model evolution toward higher-margin, less-regulated wellness offerings, moving beyond its core prescription telehealth franchise. The lack of clinical validation differentiates this from approved GLP-1 competitors like Ozempic, which the company also distributes, and suggests management believes consumer demand can sustain growth independent of regulatory clearance.
Sector implication: The announcement signals ongoing blurring of lines between pharmaceutical and wellness retail in telehealth. While it demonstrates HIMS's willingness to serve emerging consumer trends, it also highlights execution risk around regulatory compliance and reputational management in a category under heightened scrutiny.